日本語 
Hokkaido University and BostonGene are expanding their research partnership around precision oncology and AI-based cancer analysis in Japan.
The collaboration is built around BostonGene’s AI platform, which will be used to analyze tumor and immune system data collected from more than 20 different cancer types. The work includes next-generation sequencing along with combined analysis of DNA, RNA, and immune profiling taken from tumor samples.
The main concept of this research work presents an easy to understand explanation. The medical field is developing personalized cancer treatments which require hospitals and researchers to investigate the unique condition of each patient instead of using general treatment methods. The partnership works to advance its mission through dedicated efforts.
Also Read: Japan Moves Government Bond Trading to Blockchain in Major Financial Market Shift
The researchers use molecular data and immune system analysis to discover disease drivers that affect individual patients and to study immune patterns found in various cancers and to enhance treatment selection processes. The team aims to discover suitable treatments for individual patients by testing their effectiveness before treatment selection begins.
AI is becoming a much bigger part of oncology research because the amount of genomic and immune data involved is massive. Traditional analysis alone is no longer enough when researchers are dealing with this level of biological complexity.
Partnerships like this one which Japan establishes currently create a new direction for its healthcare research efforts. The universities now establish partnerships with AI and biotech companies to develop usable treatment planning systems which will enable doctors to work directly with clinical and molecular data instead of accessing it through research papers and isolated datasets.
English